Method for reducing pain with ziconotide and morphine
The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
1. A method for reducing pain in a human patient, comprising:
administering to a human patient in need thereof 0.6-27.9 μg/day of ziconotide and 0.44-20 mg/day of morphine, wherein said administering is continuous intrathecal infusion.
2. The method according to claim 1 , wherein said ziconotide is in a solution containing an antioxidant.
3. The method according to claim 2 , wherein said antioxidant is methionine.
4. The method according to claim 2 , wherein said solution has pH between 4 to 4.5.
5. The method according to claim 2 , wherein said ziconotide has a concentration of 100 μg/mL.
6. The method according to claim 1 , wherein said ziconotide is administered at 0.6-7.2 μg/day.
7. The method according to claim 1 , wherein said morphine is administered at 2-20 mg/day.
8. The method according to claim 1 , wherein said patient is treated for 14-35 days.
9. The method according to claim 1 , wherein said human patient had sub-optimal pain relief by ziconotide, or had residual pain not relieved by ziconotide and of a different nature than the pain relieved by ziconotide.
10. The method according to claim 1 , wherein said human patient had sub-optimal pain relief by morphine, or had residual pain not relieved by morphine and of a different nature than the pain relieved by morphine.
11. The method according to claim 1 , wherein said administration is performed by a drug dispensing implantable pump.